Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb’s Opdivo to be made available via EAMS

Bristol-Myers Squibb’s Opdivo to be made available via EAMS

7th November 2016

Bristol-Myers Squibb's cancer immunotherapy Opdivo has been accepted for inclusion in the UK's Early Access to Medicines Scheme (EAMS).

The Medicines Healthcare Products and Regulatory Agency has agreed to make Opdivo available through EAMS for patients with relapsed or refractory classical Hodgkin lymphoma as a monotherapy after autologous stem cell transplant and treatment with brentuximab vedotin.

This decision was based on the encouraging tumour reduction performance associated with Opdivo in recent phase II clinical trials.

Bristol-Myers Squibb's drug works by harnessing the body's own immune system to fight a number of forms of cancer, including classical Hodgkin lymphoma and advanced lung, skin and kidney cancer.

Dr Graham Collins, consultant haematologist for the Oxford University Hospitals Foundation Trust, said: "From today, these sick and often young patients will potentially be able to benefit from this new and effective medicine which we hope will provide longer survival in these patients."

The EAMS initiative was established by the government to provide patients with early access to innovative drugs that have not yet been formally approved by regulators.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801827958-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.